AstraZeneca PLC ADR (AZNN)

1,252.31
+24.03(+1.96%)
  • Volume:
    1,353
  • Bid/Ask:
    1,100.00/1,280.00
  • Day's Range:
    1,252.31 - 1,252.31

AZNN Overview

Prev. Close
1,228.28
Day's Range
1,252.31-1,252.31
Revenue
922.55B
Open
1,252.31
52 wk Range
1,061.01-1,430
EPS
2.12
Volume
1,353
Market Cap
3.88T
Dividend (Yield)
1.42
(2.20%)
Average Volume (3m)
1,232
P/E Ratio
63.80
Beta
0.174
1-Year Change
-5.42%
Shares Outstanding
1,549,841,278
Next Earnings Date
-
What is your sentiment on AstraZeneca ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
83500
  • Type:Equity
  • Market:Mexico
  • ISIN:US0463531089
  • S/N:046353108

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Analyst Price Target

Average78.00 (+14.86% Upside)
High88.00
Low65.00
Price67.91
No. of Analysts8
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuySell
SummaryStrong BuyStrong BuyStrong BuyBuyNeutral
  • do not buy this stock, it's a trap
    1
    • Junk like pfizer
      1
      • why is this stock so stagnant? even with good news it seems to drop.
        0
        • Japan, AstraZeneca agree on 120 mil. COVID-19 vaccine dose supply KYODO NEWS - 2 hours ago - 21:49 | All, Japan, Coronavirus
          1
          • I dont get how this company pumps out good news and a potential merger and the stock moves by pennies. what will it take for this stock to jump?
            0
        • Get into it before FDA approves vaccine
          2
          • is it too late to get in?
            2
            • Not really man,Its just the beginning.Its gonna be late 3 weeks after.
              0
            • I think it's a good time. this stock is stable historically and pays dividends. I bought at 62 so I'm down big but have faith it will be good long term.
              0
            • 0